Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.9% during the fourth quarter, Holdings Channel.com reports. The fund owned 13,600 shares of the biopharmaceutical company’s stock after selling 700 shares during the quarter. Louisiana State Employees Retirement System’s holdings in Regeneron Pharmaceuticals were worth $9,688,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of REGN. CWM LLC lifted its stake in Regeneron Pharmaceuticals by 1.1% during the third quarter. CWM LLC now owns 2,272 shares of the biopharmaceutical company’s stock valued at $2,389,000 after purchasing an additional 25 shares during the last quarter. Ritholtz Wealth Management increased its holdings in shares of Regeneron Pharmaceuticals by 17.6% in the third quarter. Ritholtz Wealth Management now owns 729 shares of the biopharmaceutical company’s stock valued at $766,000 after buying an additional 109 shares in the last quarter. Creative Planning lifted its position in shares of Regeneron Pharmaceuticals by 22.7% during the 3rd quarter. Creative Planning now owns 11,793 shares of the biopharmaceutical company’s stock valued at $12,397,000 after acquiring an additional 2,178 shares during the last quarter. Swedbank AB boosted its stake in shares of Regeneron Pharmaceuticals by 10.1% during the 3rd quarter. Swedbank AB now owns 149,363 shares of the biopharmaceutical company’s stock worth $157,016,000 after acquiring an additional 13,705 shares in the last quarter. Finally, Magnus Financial Group LLC grew its holdings in shares of Regeneron Pharmaceuticals by 1.3% in the 3rd quarter. Magnus Financial Group LLC now owns 1,588 shares of the biopharmaceutical company’s stock worth $1,669,000 after acquiring an additional 20 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $665.46 on Wednesday. The company has a quick ratio of 4.46, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20. The company’s fifty day moving average is $714.37 and its 200-day moving average is $906.38. The firm has a market cap of $73.13 billion, a price-to-earnings ratio of 17.38, a price-to-earnings-growth ratio of 2.38 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the prior year, the business posted $11.86 earnings per share. The business’s quarterly revenue was up 10.3% on a year-over-year basis. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.53%. The ex-dividend date is Thursday, February 20th.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Truist Financial decreased their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Wells Fargo & Company decreased their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a report on Friday, January 10th. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Barclays decreased their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Finally, Bernstein Bank cut their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.